A Durable Response to Low-Dose Afatinib After Progression on Osimertinib in Advanced Epidermal Growth Factor Receptor (EGFR) L861Q-Mutated Lung Adenocarcinoma: A Case Report
Cureus · 17.04.2026
DOI: 10.7759/cureus.107260 ↗Kurz gefasst
Fallbericht in der Zeitschrift Cureus, erschienen am 17.04.2026. Verfasst von Takayuki Higashi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Respiratory Medicine, National Hospital Organization (NHO) Kanazawa Medical Center, Kanazawa, JPN. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Respiratory Medicine, National Hospital Organization (NHO) Kanazawa Medical Center, Kanazawa, JPN.
Zitieren
APA
Higashi, T., Araya, T., Ueda, T., Hara, R., Takato, H., & Kita, T. (2026). A Durable Response to Low-Dose Afatinib After Progression on Osimertinib in Advanced Epidermal Growth Factor Receptor (EGFR) L861Q-Mutated Lung Adenocarcinoma: A Case Report. Cureus. https://doi.org/10.7759/cureus.107260
Vancouver
Higashi T, Araya T, Ueda T, Hara R, Takato H, Kita T. A Durable Response to Low-Dose Afatinib After Progression on Osimertinib in Advanced Epidermal Growth Factor Receptor (EGFR) L861Q-Mutated Lung Adenocarcinoma: A Case Report. Cureus. 2026. doi:10.7759/cureus.107260
BibTeX
@article{Higashi2026,
author = {Higashi, Takayuki and Araya, Tomoyuki and Ueda, Tsukasa and Hara, Ryo and Takato, Hazuki and Kita, Toshiyuki},
title = {A Durable Response to Low-Dose Afatinib After Progression on Osimertinib in Advanced Epidermal Growth Factor Receptor (EGFR) L861Q-Mutated Lung Adenocarcinoma: A Case Report},
journal = {Cureus},
year = {2026},
doi = {10.7759/cureus.107260}
}
EUVIMED